Trial Profile

A Phase Ib, Dose-Escalation Study of the Safety and Pharmacokinetics of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 22 May 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Drozitumab (Primary) ; Bevacizumab; Cetuximab; Fluorouracil; Folinic acid; Irinotecan
Indications Colorectal cancer
Focus Adverse reactions; Biomarker

15 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
13 Oct 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
30 Jan 2008 Status changed from recruiting to initiated. Updated from ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com